Emerald BioStructures, a biotech research firm on Bainbridge Island, WA, said today it has achieved the second milestone in a collaboration with Belgium-based UCB. The milestone, in which Emerald and UCB were able to identify new drug candidates to interact with some undisclosed protein structures, prompted the two sides to expand their collaboration, Emerald said. Financial terms of the new arrangement aren’t being disclosed, but the alliance provides enough to support “multiple full-time researcher equivalents at Emerald.” We wrote an in-depth story about Emerald’s recovery from the brink of bankruptcy back in May.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
